Vyome Holdings, Inc.
HINDAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | downgrade | Buy →Hold | Jul 17, 2024 |
| Alliance Global Partners | maintain | Buy | May 26, 2022 |
| Maxim Group | maintain | Buy | Oct 8, 2021 |
| Ladenburg Thalmann | downgrade | Buy →Neutral | Aug 3, 2018 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.20| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.10 | $-0.19 | $27.0K | $27.0K |
| May 19, 2026 | $-0.15 | $-0.15 | $31.6K | $31.6K |
| Mar 26, 2026 | $-0.47 | $-0.47 | $36.6K | $36.6K |
| Nov 14, 2025 | $-3.12 | $-0.11 | $34.6K | $34.6K |
| Aug 14, 2025 | $-2.25 | — | $249.0K | — |
| May 21, 2025 | $18.98 | — | $1.1M | — |
| Apr 4, 2025 | $-47.25 | $-406.00 | $1.8M | $3.2M |
| Nov 14, 2024 | $-0.78 | $-5.80 | $2.3M | $2.5M |
News
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND) ("Vyome"), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today congratulated its Scientific Co-Founder and Director, Dr. Shiladitya Sengupta, PhD, on his promotion to Professor of Medicine at Harvard Medical School. The academic recognition marks an important milestone in Dr. Sengupta's distinguished scientific career, spanning biomedical research, nanomedicin…
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #ocularinflammation--Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for U.S. Patent Application No. 17/787,303, titled “Formulations and Method for Treatment of Inflammatory Diseases.” The USPTO has allowed the multiple claims filed under the …
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #CFO--Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, today announced the appointment of senior financial executive Jerry Leonard, CPA, MBA, as Chief Financial Officer. Mr. Leonard has assumed the role from September 1st, 2026 and will oversee the Company's financial operations, financial reporti…
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND, “Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corporate update. Krishna Gupta, Chairman, Vyome Holdings, said, “Vyome continues to execute with focus and discipline across its development programs while maintaining a methodical and conservative approach to capi…